Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional)
The summary for the Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-19-009 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).
Federal Grant Title: | Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-19-504 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.393, 93.399, 93.847 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | December 17th, 2019 |
Original Application Deadline: | December 17th, 2019 |
Posted Date: | September 26th, 2019 |
Creation Date: | September 26th, 2019 |
Archive Date: | January 22nd, 2020 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | September 26th, 2019 |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see the funding announcement for the eligibility details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-504.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
- • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
- • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
- • Pilot Studies in Pancreatic Cancer
- • Cancer Prevention Research Small Grant Program
- • Molecular Targets for Nutrients in Prostate Cancer Prevention
- More Grants from the National Institutes of Health
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...